Skip to main content

Table 1 Maltonis mean IC50 values in a panel of human derived sarcoma and human normal mesenchymal cells

From: An aza-macrocycle containing maltolic side-arms (maltonis) as potential drug against human pediatric sarcomas

Histotypea Cell lineb IC50 μM (± SE)c,f Genetic alterationd Doubling time (hours)e,f
RHABDOMYOSARCOMA RD/18 6.8 (± 2.1) Altered 11p15.5 chromosome 22 ± 0.1
  SJ-RH4 5.6 (± 1.3) (2;13)(q35;q14) PAX3 FKHR 25 ± 1.2
  SJ-RH30 9.9 (± 2.7) (2;13)(q35;q14) PAX3 FKHR 26 ± 1.0
OSTEOSARCOMA IOR/OS10 5.5 (± 1.3) Complex Karyotype 30.4 ± 2.6
  IOR/OS9 8.6 (± 1.8) Complex Karyotype 44.5 ± 2.4
  Saos-2 11.9 (± 3.1) Complex Karyotype 36.1 ± 4.4
  Saos-2/DX580 39.3 (± 2.6) Complex Karyotype 75.6 ± 5.7
  Saos-2/CDDP6ug 43.3 (± 6.8) Complex Karyotype 44.3 ± 4.1
  U-2OS 12.5 (± 0.7) Complex Karyotype 18.3 ± 0.2
  U-2OS/DX580 16.5 (± 0.4) Complex Karyotype 45.3 ± 4.7
  U-2OS/CDDP4ug 56.1 (± 1.4) Complex Karyotype 38.6 ± 4.1
EWING SARCOMA 6647 3.1 (± 1.4) t(11;22)(q24;q12) EWSR1-FLI1 TYPE II 29 ± 2.3
  LAP-35 11.6 (± 0.7) t(11;22)(q24;q12) EWSR1-FLI1 TYPE II 48.6 ± 4.2
  SK-N-MC 3.9 (± 0.5) t(11;22)(q24;q12) EWSR1-FLI1 TYPE I 26.9 ± 0.5
  TC-71 2.6 (± 1.4) t(11;22)(q24;q12) EWSR1-FLI1 TYPE I 14.9 ± 1.4
  TC/DOXO8 5.0 (± 0.1) t(11;22)(q24;q12) EWSR1-FLI1 TYPE I 22.6 ± 2.8
h-MSC MES1 >50 n.d. n.d.
  MES2 >50 n.d. n.d.
  DP-15 >50 n.d. n.d.
  1. aHistotype: origin of the patient-derived cell line.
  2. bcell line name.
  3. cmean IC50 calculated over three idependent experiments ± SE.
  4. dgenetic alterations associated to the cell line.
  5. edoubling time of the indicated cell line.
  6. fIC50 values statistically correlate with cell doubling times (r = 0.59, p = 0.01, Pearson correlation test).
  7. n.d. not determined.